Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02871843
Title Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications

gliosarcoma

high grade glioma

glioblastoma

Therapies

RRx-001 + Temozolomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.